Biogen Handily Tops Quarterly Views; All Eyes On Alzheimer's Disease

Biogen Handily Tops Quarterly Views; All Eyes On Alzheimer's Disease

Biogen stock edged higher Wednesday after the biotech company topped Wall Street's second-quarter expectations, but didn't shed much light on its Alzheimer's treatment efforts.